Acrivon Therapeutics (ACRV) to Release Quarterly Earnings on Wednesday

Acrivon Therapeutics (NASDAQ:ACRV) is projected to release its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect Acrivon Therapeutics to announce earnings of ($0.49) per share and revenue of $0.3860 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 4:00 PM ET.

Acrivon Therapeutics (NASDAQ:ACRV) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.49) earnings per share for the quarter, meeting the consensus estimate of ($0.49). On average, analysts expect Acrivon Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Acrivon Therapeutics Stock Performance

Shares of Acrivon Therapeutics stock opened at $1.56 on Wednesday. The company’s 50-day moving average price is $1.65 and its 200-day moving average price is $1.69. Acrivon Therapeutics has a 12-month low of $1.20 and a 12-month high of $3.56. The company has a market cap of $66.77 million, a price-to-earnings ratio of -0.78 and a beta of 1.85.

Institutional Trading of Acrivon Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Focus Partners Wealth bought a new stake in shares of Acrivon Therapeutics during the 3rd quarter valued at about $36,000. Schonfeld Strategic Advisors LLC bought a new position in shares of Acrivon Therapeutics in the fourth quarter worth approximately $40,000. Vermillion & White Wealth Management Group LLC bought a new position in shares of Acrivon Therapeutics in the fourth quarter worth approximately $44,000. Quadrature Capital Ltd purchased a new stake in Acrivon Therapeutics in the fourth quarter valued at approximately $50,000. Finally, Invesco Ltd. purchased a new stake in Acrivon Therapeutics in the first quarter valued at approximately $72,000. Hedge funds and other institutional investors own 71.62% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of Acrivon Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Acrivon Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $11.67.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.